Both will be presenting. Both have papers that look at the MOA and both have papers that report older findings. But only Vertex will be presenting one of the late breaking papers and Vertex has indicated that they will be sharing recent data at that time.
On the other hand, Idenix will not be sharing any late breaking data.
In literature there was a recent preclinical work which showed that Pol I. was antagonistic with RBV. That is why NM283 trial includes only IFN and no RBV. If this trial shows a good overall response, this nucleoside-analog Pol I. could be a potential partner drug to TVR.